KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2016 - 2017)

Regeneron Pharmaceuticals (REGN) has 9 years of Long-Term Debt Repayments data on record, last reported at -$25000.0 in Q4 2017.

  • For Q4 2017, Long-Term Debt Repayments fell 100.77% year-over-year to -$25000.0; the TTM value through Sep 2018 reached -$25000.0, down 100.11%, while the annual FY2017 figure was $19.9 million, 290.2% up from the prior year.
  • Long-Term Debt Repayments reached -$25000.0 in Q4 2017 per REGN's latest filing, up from -$37.1 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $140.1 million in Q4 2015 and bottomed at -$62.2 million in Q4 2014.
  • Average Long-Term Debt Repayments over 5 years is $9.9 million, with a median of $640000.0 recorded in 2016.
  • Peak YoY movement for Long-Term Debt Repayments: soared 17539.94% in 2014, then crashed 5892.97% in 2017.
  • A 5-year view of Long-Term Debt Repayments shows it stood at -$3.6 million in 2013, then crashed by 1605.12% to -$62.2 million in 2014, then skyrocketed by 325.11% to $140.1 million in 2015, then plummeted by 97.68% to $3.2 million in 2016, then tumbled by 100.77% to -$25000.0 in 2017.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were -$25000.0 in Q4 2017, -$37.1 million in Q3 2017, and $44.1 million in Q2 2017.